SCHEMBL2363468

SCHEMBL2363468

CC(C)C1CCC(C)(OC[C@H](O)CO)CC1

nearest known ligand 0.32

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL121847 1.00 USP2 (0.32) USP2
SCHEMBL375500 1.00 USP2 (0.32) USP2
SCHEMBL6563549 0.85
SCHEMBL15988037 0.84
SCHEMBL5090272 0.80
Propylene Glycol SCHEMBL6009699 0.78 HSD17B10 (0.32) USP2
SCHEMBL248362 0.77
SCHEMBL4594905 0.77 TRPA1 (0.33)
SCHEMBL119537 0.77 TRPA1 (0.33)
SCHEMBL6139804 0.77 PRKCA (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3031892-B1 A PROCESS FOR MAKING A CONSUMER GOODS PRODUCT COMPRISING A BENEFIT DELIVERY COMPOSITION PROCTER & GAMBLE (US) 2020-02-26 EP disclosed
EP-3144375-B1 A PROCESS FOR MAKING A DETERGENT COMPOSITION PROCTER & GAMBLE (US) 2018-12-26 EP disclosed
EP-2892620-B1 MOUTH RINSES AND TOOTH SENSITIVITY TREATMENT COMPOSITIONS JOHNSON & JOHNSON CONSUMER INC (US) 2018-05-02 EP disclosed
EP-3031893-B1 A PROCESS FOR MAKING A CONSUMER GOODS PRODUCT COMPRISING A BENEFIT DELIVERY COMPOSITION PROCTER & GAMBLE (US) 2017-11-08 EP disclosed
US-20170081620-A1 PROCESS FOR MAKING A DETERGENT COMPOSITION THE PROCTER & GAMBLE COMPANY 2017-03-23 US disclosed
EP-3144375-A1 A PROCESS FOR MAKING A DETERGENT COMPOSITION The Procter and Gamble Company (US) 2017-03-22 EP disclosed
US-20160166492-A1 PROCESS FOR MAKING A BENEFIT DELIVERY COMPOSITION THE PROCTER & GAMBLE COMPANY 2016-06-16 US disclosed
WO-2016094600-A1 A PROCESS FOR MAKING A CONSUMER GOODS PRODUCT COMPRISING A BENEFIT DELIVERY COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 2016-06-16 WO disclosed
WO-2016094599-A1 A PROCESS FOR MAKING A CONSUMER GOODS PRODUCT COMPRISING A BENEFIT DELIVERY COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 2016-06-16 WO disclosed
US-20160166493-A1 PROCESS FOR MAKING A BENEFIT DELIVERY COMPOSITION THE PROCTER & GAMBLE COMPANY 2016-06-16 US disclosed
US-20140113971-A1 Topical NSAID Compositions Having Sensate Component ZHANG JOANNA (US) 2014-04-24 US disclosed
WO-2014039966-A2 MOUTH RINSES AND TOOTH SENSITIVITY TREATMENT COMPOSITIONS JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2014-03-13 WO disclosed
US-20140072519-A1 MOUTH RINSES AND TOOTH SENSITIVITY TREATMENT COMPOSITIONS JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2014-03-13 US disclosed
US-8084050-B2 Menthol for cooling, tingling sansation, guar hydroxypropyltrimonium chloride a cataionic polymer, solubilizer selected from methanol, ethanol, isopropanol, glycerol, ethylene glycol, diethylene glycol, propylene glycol, polypropylene glycol, polyethylene glycol; oral and personal care applications COLGATE-PALMOLIVE COMPANY (US) 2011-12-27 US disclosed
US-20110237674-A1 TOPICAL NSAID COMPOSITIONS HAVING SENSATE COMPONENT NOVARTIS AG (CH) 2011-09-29 US disclosed
EP-2349248-A2 TOPICAL NSAID COMPOSITIONS HAVING SENSATE COMPONENT Novartis AG (CH) 2011-08-03 EP disclosed
WO-2010045415-A2 TOPICAL NSAID COMPOSITIONS HAVING SENSATE COMPONENT NOVARTIS AG (CH) 2010-04-22 WO disclosed
EP-2088993-A1 COMPOSITIONS COMPRISING COMBINATIONS OF SENSATES Colgate-Palmolive Company (US) 2009-08-19 EP disclosed
WO-2008045678-A1 COMPOSITIONS COMPRISING COMBINATIONS OF SENSATES COLGATE- PALMOLIVE COMPANY (US) 2008-04-17 WO disclosed
US-20080089850-A1 Compositions Comprising Combinations of Sensates COLGATE-PALMOLIVE COMPANY 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160166492-A1 PROCESS FOR MAKING A BENEFIT DELIVERY COMPOSITION CETP, FABP4, LIPA USP2 4017/4885
US-20110237674-A1 TOPICAL NSAID COMPOSITIONS HAVING SENSATE COMPONENT TRPA1, TRPV1, PTGES USP2 3221/4885
US-20140113971-A1 Topical NSAID Compositions Having Sensate Component TRPA1, TRPV1, PTGES USP2 3221/4885
US-20160166493-A1 PROCESS FOR MAKING A BENEFIT DELIVERY COMPOSITION CETP, SCD, SURF4 USP2 3879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.